We're on a mission to make disease intelligence understandable, trustworthy and accessible to everyone — built on award-winning science and rooted in European values of privacy and transparency.
Outbreak information is everywhere, but it's fragmented, technical and often alarming. Mediscanner brings it together in one place and translates it into plain language — so anyone can understand their risk and know what to do.
We believe health literacy is a form of public health. Every feature we build — from the symptom checker to the games — exists to help people learn, prepare and act with confidence, never to frighten or to replace professional care.
We're working towards collaborations with academic and public-health institutions to strengthen the platform's scientific rigour and oversight.
Our founding work earned recognition in the Viruskenner programme for outstanding science communication about viruses and outbreaks.
We set out to build the tool we wished existed — one place to understand symptoms, track outbreaks and learn, without the noise.
We engineered Mediscanner around GDPR from day one: symptom checks run in your browser, and we minimise every byte of data we touch.
The platform now tracks 268 pathogens, presents an illustrative disease map, and curates dozens of health stories a day from official feeds.
We're pursuing collaborations with academic and public-health institutions to deepen oversight and expand verified sources.
We collect the minimum, store as little as possible, and keep sensitive checks on your device.
We label what's informational, cite our sources, and never overstate what the tool can do.
We explain risk calmly and practically, helping people act rather than panic.
Free to use, no account required, and designed to be understood by everyone.
GDPR, EU MDR scoping and a published DPIA — compliance isn't an afterthought.
We expand our data, refine our science and listen to the people who rely on us.
We'd love to hear from researchers, clinicians and public-health teams. Reach out and let's talk.